Articles tagged with Clinical Trials
The study found that 5-year freedom from biochemical failure stands at 68%, comparable to other salvage modalities. At 10 years, the rate dropped to 54%. Late Grade 3 gastrointestinal and genitourinary adverse events occurred in 14% of participants.
A combination approach of catheter ablation and ethanol infusion significantly reduced atrial fibrillation recurrence rates, with 49% remaining free from AFib after six months. This finding supports the use of the Vein of Marshall Ethanol for Untreated Persistent Atrial Fibrillation (VENUS) trial's treatment as a first-line therapy.
A new study examines clinical trials involving radiation therapy from 1996 to 2019 and finds that Black and Asian American patients are underrepresented, with 12% and 3% of trial participants respectively. The findings highlight the need for better inclusion of racial minorities in research studies.
A randomized clinical trial found that electroacupuncture significantly reduced pain severity among adults with chronic low back pain. The study compared the effects of electroacupuncture to a placebo treatment, with results indicating a notable decrease in pain severity.
A randomized phase III trial found that image-guided intensity modulated radiation therapy (IMRT) improves long-term toxicity-free survival and reduces gastrointestinal side effects in women with cervical cancer. The study showed a significant reduction in moderate-to-severe gastrointestinal side effects compared to 3D-CRT, with improv...
A phase II trial found no statistically significant overall survival differences between dose-intensification radiation therapy (IMRT) and standard-dose radiation therapy with temozolomide treatments. However, MGMT methylation and RPA were predictive of progression-free survival.
The study found that MFS was strongly correlated with OS (τ = 0.86), while BF and DM were only moderately and weakly correlated with OS, respectively. The analysis suggests that researchers should be cautious when inferring clinical benefit from studies using biochemical failure as a surrogate for overall survival.
The NRG-RTOG 0712 trial demonstrated high efficacy rates for both gemcitabine and daily radiation regimens, with 79% and 85% distant metastasis-free rates at 3 years, respectively. The findings confirm the acceptance of these treatments as alternatives to cystectomy.
A clinical trial published in the New England Journal of Medicine shows that finerenone significantly slows the progression of diabetic kidney disease by 18% compared to a placebo. The study also found a reduction in cardiovascular event rates, offering new treatment options for patients with chronic kidney disease and type 2 diabetes.
Recent clinical trials have shown promising results for finerenone, which slows diabetic kidney disease progression and reduces cardiovascular events when added to standard care. Empagliflozin also demonstrated benefits in patients with heart failure and chronic kidney disease. These findings suggest new treatment options for patients ...
Current Covid-19 vaccine trials are not designed to detect a reduction in serious outcomes such as hospitalisations, intensive care use, or deaths. The trials evaluate mild disease and may not provide evidence of vaccine effectiveness in preventing severe illness or transmission.
Researchers consider indirect protection strategies due to potential ineffectiveness in elderly and comorbid individuals. Indirect effects are harder to measure than direct effects, highlighting the need for evidence on vaccine impact before approval or soon after.
The study found that tocilizumab significantly improved survival rates among adults hospitalized with moderate-to-severe COVID-19 pneumonia compared to standard care. By reducing mortality and shortening hospital stays, the treatment offers a promising alternative for critically ill patients.
Researchers found that tocilizumab, an anti-inflammatory drug, reduced mortality by 30 percent in critically ill COVID-19 patients when administered early in ICU care. The study analyzed data from over 4,000 patients with COVID-19 and found consistent benefits across age, sex, and illness severity.
Researchers at University of Chicago Medicine are launching a four-year trial to test two interventions for personalized diabetes care in older adults. The 'My Diabetes, My Community' trial incorporates personalized sugar control goals, telephonic care management, and community-based resource access.
The FORECAST trial found that fractional flow reserve derived from computed tomography coronary angiography (FFRCT) reduced the use of invasive coronary angiography by 22% without significantly reducing costs. The strategy also showed promise in terms of reducing healthcare utilization and improving patient outcomes.
The TARGET FFR trial found that a physiology-guided incremental optimization strategy (PIOS) reduced the proportion of patients with a final post-PCI FFR ?0.80, while also improving mean Coronary Flow Reserve. The study's results suggest potential benefits for PCI outcomes.
The MITHRAS trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair was not superior to conservative medical treatment. The study also revealed that the presence of a persistent iASD is associated with increased long-term mortality and morbidity following TMVR.
Researchers from the University of Minnesota developed a bimodal neuromodulation treatment using sound and electrical stimulation to reduce tinnitus symptoms. The study, published in Science Translational Medicine, showed significant improvements in symptom severity for 86% of participants after 12 weeks of treatment.
A new self-expanding bioprosthetic valve used in TAVR failed to demonstrate non-inferiority compared to an existing valve. The SCOPE II Trial found increased rates of cardiac death and moderate-severe aortic regurgitation with the new valve.
The REFLECT II trial evaluated the safety and effectiveness of TriGuard 3, a self-stabilizing cerebral embolic deflection filter, in patients undergoing TAVR. The device met the primary safety endpoint, but did not demonstrate superiority for reducing ischemic stroke or larger lesions.
A Phase 1/2 randomised controlled trial found the vaccine candidate BBIBP-CorV is safe and induces an immune response in healthy volunteers. The study detected antibody responses in all recipients by day 42 after vaccination, and was well-tolerated with no severe adverse reactions reported.
A new study found that personal and psychological characteristics significantly impact progress in workplace wellness programs. The research suggests that tailoring nudges to an individual's behavior profile can unlock full potential, leading to improved outcomes. For some groups, ongoing incentives may be necessary to sustain motivation.
A randomized clinical trial found that different fitness strategies were effective for distinct subgroups of participants based on their personality and behavioral characteristics. These subgroups included extroverted and motivated individuals, less active and less social participants, and those who were less motivated and at-risk.
The PROSPECT ABSORB trial found PCI safe with favorable long-term outcomes for non-flow-limiting vulnerable plaques. Follow-up lumen areas were substantially enlarged in BVS-treated lesions compared to GDMT alone.
The COMBINE (OCT-FFR) trial found that the presence of TCFA is a strong predictor of future MACE, despite lack of ischemia. Combining FFR and OCT can improve accuracy of high-risk lesion identification in patients with diabetes.
The NIH has launched the ACTIV-5 Big Effect Trial to determine whether certain approved therapies or investigational drugs show promise against COVID-19. The study will enroll adult volunteers hospitalized with COVID-19 at up to 40 US sites and test three investigational treatments against a placebo.
A Phase I trial found neoadjuvant combination immunotherapy with tremelimumab and durvalumab showed early signs of activity in patients with high-risk disease, with a pathologic complete response rate of 37.5%.
Researchers at NHGRI conducted a study to better understand the needs of patients with sickle cell disease regarding genome editing clinical trials. Participants showed higher genetic literacy levels than expected, but emphasized the need for accessible information about risks and benefits.
UT Southwestern Medical Center's COVID-19 adjustments streamlined clinical trials, allowing for remote consents and telehealth visits. A survey of UTSW clinical research professionals found positive experiences with these changes, with over 90% supporting continued use after the pandemic ends.
Researchers found that antibiotics were not worse than surgery in terms of overall health status, allowing most people to avoid operations. Patients treated with antibiotics often returned home faster but missed less time from work and school.
The SWOG Cancer Research Network will share innovative approaches to cancer care, including telemedicine and quality improvements, in response to the COVID-19 pandemic. The network's trials have led to significant advancements in cancer treatment and patient outcomes.
A single fungicide application at the silking stage provides the best foliar disease control in Kentucky corn crops, according to research by Carl Bradley and colleagues. This approach is more cost-effective than sequential applications, allowing farmers to improve their return on investment.
The CODA Trial found that antibiotics were not worse than surgery in measuring overall health status, allowing most people to avoid operations in the short term. Patients treated with antibiotics more often returned to the emergency department but missed less time from work and school.
Influenza vaccination has shown promise in preventing cardiovascular complications from COVID-19, particularly in high-risk patients. Three ongoing trials are evaluating the cardioprotective effects of different influenza vaccine formulations and may inform future efforts to develop targeted interventions.
Researchers found that minority-serving hospitals offer a strong level of evidence-based care for early-stage breast cancer, with similar rates of following recommended surgical procedures as non-minority hospitals. However, disparities exist in access to high-quality care and adherence to treatment guidelines among minority-serving ho...
A new investigation by Science reveals that the FDA's enforcement of clinical trial regulations is often light-handed, slow-moving, and secretive. The agency rarely levels sanctions or disqualifies scientists from clinical research, and cases are frequently resolved based on unverified claims.
A Phase 1 trial of an investigational mRNA COVID-19 vaccine has shown that the vaccine is well-tolerated and generates a strong immune response in older adults, with comparable efficacy to younger age groups. The study enrolled 40 healthy volunteers aged 56-71 years, who received two doses of the vaccine.
A randomized clinical trial found daily hydroxychloroquine did not prevent SARS-CoV-2 infection in hospital-based healthcare workers. The trial was terminated early due to lack of efficacy.
The National Institutes of Health has awarded grants to support researchers' efforts in using tiny, bioengineered models of human tissues and organ systems to study diseases and test drugs. The goal is to develop ways to predict which patients are most likely to benefit from an investigational therapy prior to initiating clinical trials.
Insilico Medicine will showcase its latest AI advancements in drug discovery and productive longevity at the Leveraging Intelligent Tech for Drug Development Forum. The company's work on AI-generated molecular structures, synthetic biological data, and clinical trial prediction has garnered significant attention and funding.
Researchers at MUSC are using new technologies to conduct remote smoking cessation clinical trials, reaching smokers in rural areas and beyond. With electronic consent and smartphone-enabled devices, participants can complete trials from home, providing more representative data.
A new TB vaccine developed by Dartmouth's Geisel School of Medicine has shown promising results in a Phase 2 trial, inducing immune responses against the disease. The vaccine was safe and well-tolerated, with minimal local reactions, and may prevent TB disease by inducing a favorable immune response.
A study published in JAMA Internal Medicine reveals that older persons are highly likely to be excluded from COVID-19 clinical trials, despite accounting for 30-40% of cases and 80% of deaths globally. The exclusion poses a risk to the effectiveness and safety of treatments for older adults.
Randomized clinical trials for COVID-19 treatments and vaccines often exclude older adults, according to a new study. The study found that the likelihood of excluding older persons is significant in these trials, raising concerns about equity and inclusivity.
The FDA has approved Nucala for use in treating patients with hypereosinophilic syndrome, a life-threatening group of blood disorders. The drug reduces disease flares and improves health without substantial side effects.
A randomized clinical trial found that restricting daily eating to between 12 pm and 8 pm resulted in significant weight loss among participants. The study also showed improvements in metabolic markers, suggesting a potential therapeutic strategy for obesity.
A new drug, vamorolone, has shown promise in reducing side effects associated with current steroid treatments for Duchenne muscular dystrophy. Interim results from a 24-month clinical trial suggest that vamorolone may retain or improve the therapeutic benefits of steroids while minimizing risks.
A fourth Phase 3 clinical trial has begun enrolling adult volunteers to evaluate the investigational Janssen COVID-19 vaccine. The trial aims to assess the vaccine's ability to prevent symptomatic COVID-19 after a single dose regimen.
A new Mayo Clinic study found that clinical oncologists are less informed about the federal Right to Try (RTT) law, citing concerns over patient safety and regulatory burden. The study also revealed that most oncologists had limited familiarity with RTT despite having experience with FDA's Expanded Access Programs.
The National Institutes of Health (NIH) is expanding two randomized, placebo-controlled clinical trials to evaluate the effectiveness and safety of convalescent plasma as a treatment for patients hospitalized with COVID-19. The trials aim to assess clinical improvement measures and resource needs, such as ventilators.
A pioneering study by Massachusetts General Hospital researchers found light therapy to be safe and measurable in the brain, showing promise as a treatment for TBI. The study included 68 patients with moderate traumatic brain injury and found statistically significant differences in myelin integrity surrounding neurons.
Researchers found that a hybrid strategy combining electronic medical records with postal mailings is more effective than traditional methods in recruiting diverse participant populations. This approach increased participation among underrepresented groups, including Black participants and women, while being cost-effective.
A randomized clinical trial compared two smartphone apps for helping smokers quit, with one approach using gamification and the other leveraging cognitive behavioral therapy. The study found that both apps were effective in reducing cigarette use, but the gamified app had a higher quit rate at 6-month follow-up.
A VCU study reveals an experimental cancer drug called AR-12 may be effective against SARS-CoV-2, inhibiting viral infection and replication. The oral treatment has shown promise in previous studies, including against other viruses like Zika and influenza.
A phase 3 trial found that combining nivolumab and cabozantinib was superior to sunitinib for progression-free survival, overall survival, and response rate in patients with metastatic kidney cancer. The treatment reduced the risk of progression or death by almost 50%.
The University of Montana has received a five-year, $33.4 million award from the National Institutes of Health to develop and conduct clinical trials for opioid vaccines. The UM vaccine research team will advance lead opioid vaccine candidates to Phase I human clinical trials with funding from the NIH HEAL Initiative.
A study presented at ESMO 2020 found significant variations in access to cancer medicines and clinical trials across European countries. Western European nations tend to have more clinical trials, while Eastern and Central European countries face barriers due to limited infrastructure and resources.
A Phase II trial found that a combination of ipilimumab and nivolumab generated durable responses in 25% of patients with metastatic castration-resistant prostate cancer. The treatment achieved disease control in 46.9% of patients, with median progression-free survival of 5.5 months.
Researchers tested the ReWalk ReStore soft robotic exosuit for safety, reliability, and feasibility in post-stroke rehabilitation. The device improved gait patterns and walking speeds, with over a third of participants achieving significant increases in unassisted walking speed.